866-997-4948(US-Canada Toll Free)

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 32 Pages

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2016, provides in depth analysis on Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
- The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Overview 6
Therapeutics Development 7
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Stage of Development 7
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Therapy Area 8
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Indication 9
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Products Glance 10
Early Stage Products 10
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Companies 11
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Universities/Institutes 13
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 19
Amgen Inc. 19
Millennium Pharmaceuticals Inc 20
ProNAi Therapeutics, Inc. 21
SBI Biotech Co., Ltd. 22
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drug Profiles 23
MSK-777 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
PNT-141 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Small Molecule to Inhibit Cdc7/ASK for Oncology - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecules to Inhibit CDC7 for Oncology - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
TAK-931 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Dormant Projects 29
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Discontinued Products 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 31
Disclaimer 32

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by Amgen Inc., H2 2016 19
Pipeline by Millennium Pharmaceuticals Inc, H2 2016 20
Pipeline by ProNAi Therapeutics, Inc., H2 2016 21
Pipeline by SBI Biotech Co., Ltd., H2 2016 22
Dormant Projects, H2 2016 29
Discontinued Products, H2 2016 30

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Actions, H2 2016 16
Number of Products by Stage and Routes of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *